Current Pharmacology Reports

, Volume 4, Issue 2, pp 112–119 | Cite as

Novel Insights in the Management of Dyslipidemia in Patients With HIV Infection

  • Marianthi Papagianni
  • Symeon Metallidis
  • Konstantinos Tziomalos
Cardiovascular Pharmacology (J Ndisang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Cardiovascular Pharmacology


Purpose of the Review

In recent years, cardiovascular diseases (CVD) have become a leading cause of death in patient with HIV infection, despite a reduction of total mortality in this population. Patients with HIV who are receiving antiretroviral therapy (ART) have approximately 1.5–2 times higher risk for cardiovascular events than HIV-uninfected people. Dyslipidemia is a major risk factor for CVD and is more prevalent in patients with HIV infection. In the present review, we summarize the current concepts in the management of dyslipidemia in patients with HIV infection.

Recent Findings

Several studies evaluated the safety and effectiveness of statins in the management of dyslipidemia in patients with HIV infections. However, most studies are small and short term and none evaluated the effects of statins on cardiovascular morbidity. There are also very limited data on the role of other lipid-lowering agents in these patients. Moreover, the effect of switching ART on the lipid profile and on viral suppression is also unclear.


Management of dyslipidemia in patients with HIV infection is complicated by the increased risk for pharmacokinetic interactions between lipid-lowering agents and ART as well as by the adverse metabolic effects of most classes of ART. However, given the increased cardiovascular risk of this population, lipid-lowering treatment, primarily with statins, should be considered and appears to be equally effective as in non-HIV infected subjects.


HIV infection Statins Ezetimibe Fenofibrate Dyslipidemia Antiretroviral treatment 


Compliance with Ethical Standards

Conflict of Interest


Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Feinstein MJ, Bahiru E, Achenbach C, Longenecker CT, Hsue P, So-Armah K, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117(2):214–20. Scholar
  2. 2.
    •• Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241–8. An important study showing that cardiovascular disease represents an important cause of death in patients with HIV infection.CrossRefPubMedGoogle Scholar
  3. 3.
    Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12. Scholar
  4. 4.
    Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13(8):453–68. Scholar
  5. 5.
    • Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–22. An important study showing that patients with HIV infection have increased risk for myocardial infarction compared with the general population.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52. Scholar
  7. 7.
    O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761–75. Scholar
  8. 8.
    Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–39.CrossRefGoogle Scholar
  9. 9.
    Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M, et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012;13(3):153–61. Scholar
  10. 10.
    Singh S, Willig JH, Mugavero MJ, Crane PK, Harrington RD, Knopp RH, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52(3):387–95. Scholar
  11. 11.
    Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24(1):77–83. Scholar
  12. 12.
    Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS. 2003;17(6):851–9. Scholar
  13. 13.
    Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4:e284–94.CrossRefPubMedGoogle Scholar
  14. 14.
    Rahman AP, Eaton SA, Nguyen ST, Bain AM, Payne KD, Bedimo R, et al. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. Pharmacotherapy. 2008;28(7):913–9. Scholar
  15. 15.
    Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6(6):572–8. Scholar
  16. 16.
    Bittar R, Giral P, Aslangul E, Assoumou L, Valantin MA, Kalmykova O, et al. Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor. AIDS. 2012;26(14):1801–5. Scholar
  17. 17.
    Nixon DE, Bosch RJ, Chan ES, Funderburg NT, Hodder S, Lake JE, et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group study A5275). J Clin Lipidol. 2017;11(1):61–9. Scholar
  18. 18.
    Nou E, Lu MT, Looby SE, Fitch KV, Kim EA, Lee H, et al. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS. 2016;30(4):583–90. Scholar
  19. 19.
    Hileman CO, Turner R, Funderburg NT, Semba RD, McComsey GA. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS. 2016;30(1):65–73. Scholar
  20. 20.
    Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016;37(48):3600–9. Scholar
  21. 21.
    Bittar R, Aslangul É, Giral P, Assoumou L, Valantin MA, Kalmykova O, et al. Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors. C R Biol. 2017;340(2):109–13. Scholar
  22. 22.
    •• Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015;2:e52–63. A recent study showing the effects of atorvastatin on subclinical atherosclerosis in patients with HIV infection.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68(4):396–404. Scholar
  24. 24.
    Calza L, Vanino E, Salvadori C, Manfredi R, Colangeli V, Cascavilla A, et al. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. HIV Clin Trials. 2014;15(1):1–13. Scholar
  25. 25.
    Melvin AJ, Montepiedra G, Aaron L, Meyer WA 3rd, Spiegel HM, Borkowsky W, et al. Safety and efficacy of atorvastatin in human immunodeficiency virus-infected children, adolescents and young adults with hyperlipidemia. Pediatr Infect Dis J. 2017;36(1):53–60. Scholar
  26. 26.
    De Wit S, Delforge M, Necsoi CV, Clumeck N. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS. 2011;25(10):1332–3. Scholar
  27. 27.
    Weijma RG, Vos ER, Ten Oever J, Van Schilfgaarde M, Dijksman LM, Van Der Ven A, et al. The effect of Rosuvastatin on markers of immune activation in treatment-Naïve human immunodeficiency virus-patients. Open Forum Infect Dis. 2015;3:ofv201.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Calza L, Colangeli V, Magistrelli E, Contadini I, Bon I, Re MC, et al. Significant decrease in plasma levels of D-dimer, interleukin-8, and interleukin-12 after a 12-month treatment with Rosuvastatin in HIV-infected patients under antiretroviral therapy. AIDS Res Hum Retrovir. 2017;33(2):126–32. Scholar
  29. 29.
    Dirajlal-Fargo S, Kinley B, Jiang Y, Longenecker CT, Hileman CO, Debanne S, et al. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. AIDS. 2015;29(3):313–21. Scholar
  30. 30.
    Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59(8):1148–56. Scholar
  31. 31.
    Elahi S, Weiss RH, Merani S. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS. 2016;30(2):171–83. Scholar
  32. 32.
    Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, et al. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Tropical Med Int Health. 2015;20(3):380–90. Scholar
  33. 33.
    Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203(6):756–64. Scholar
  34. 34.
    Weiss L, Chevalier MF, Assoumou L, Paul JL, Alhenc-Gelas M, Didier C, et al. Rosuvastatin is effective to decrease CD8 T-cell activation only in HIV-infected patients with high residual T-cell activation under antiretroviral therapy. J Acquir Immune Defic Syndr. 2016;71(4):390–8. Scholar
  35. 35.
    Hu G, Li X, Sun X, Lu W, Liu G, Huang J, et al. Identification of old drugs as potential inhibitors of HIV-1 integrase-human LEDGF/p75 interaction via molecular docking. J Mol Model. 2012;18(12):4995–5003. Scholar
  36. 36.
    Overton ET, Sterrett S, Westfall AO, Kahan SM, Burkholder G, Zajac AJ, et al. Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. AIDS. 2014;28(17):2627–31. Scholar
  37. 37.
    Calza L, Manfredi R, Colangeli V, Trapani FF, Salvadori C, Magistrelli E, et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retrovir. 2013;29(3):547–56. Scholar
  38. 38.
    •• Longenecker CT, Sattar A, Gilkeson R, McComsey GA. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016;30:2195–203. A recent study showing the effects of rosuvastatin on subclinical atherosclerosis in patients with HIV infection. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    •• Lang S, Lacombe JM, Mary-Krause M, Partisani M, Bidegain F, Cotte L, et al. Is impact of statin therapy on all-cause mortality different in HIV-infected individuals compared to general population? Results from the FHDH-ANRS CO4 cohort. PLoS One. 2015;10:e0133358. A nationwide study showing that statins might reduce all-cause mortality in HIV-infected patients.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, Obel N. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One. 2013;8(3):e52828. Scholar
  41. 41.
    Ou HT, Chang KC, Li CY, Yang CY, Ko NY. Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: a nation-wide longitudinal cohort study 2000-2011. Int J Cardiol. 2017;230:592–8. Scholar
  42. 42.
    Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top Antivir Med. 2015;23(4):146–9.PubMedGoogle Scholar
  43. 43.
    Calza L, Magistrelli E, Colangeli V, Borderi M, Contadini I, Bon I, et al. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients. AIDS. 2017;31(5):681–8. Scholar
  44. 44.
    Boonmuang P, Nathisuwan S, Chaiyakunapruk N, Suwankesawong W, Pokhagul P, Teerawattanapong N, et al. Characterization of statin-associated myopathy case reports in Thailand using the health product vigilance center database. Drug Saf. 2013;36(9):779–87. Scholar
  45. 45.
    Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42. Scholar
  46. 46.
    Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–64. Scholar
  47. 47.
    Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Rosuvastatin worsens insulin resistance in HIV-infected adults on antiretroviral therapy. Clin Infect Dis. 2015;61(10):1566–72. Scholar
  48. 48.
    Stolbach A, Paziana K, Heverling H, Pham P. A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol. 2015;11(3):326–41. Scholar
  49. 49.
    Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95. Scholar
  50. 50.
    Stradling C, Chen YF, Russell T, Connock M, Thomas GN, Taheri S. The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis. PLoS One. 2012;7(6):e38121. Scholar
  51. 51.
    van den Berg-Wolf M, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDs. 2008;22:483–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007;6(1):15. Scholar
  53. 53.
    Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G. Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 2015;14(1):57. Scholar
  54. 54.
    Leyes P, Martínez E, Larrousse M, Cofán M, Trabal J, Pérez-Heras AM, et al. Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial. BMC Infect Dis. 2014;14(1):497. Scholar
  55. 55.
    Chow D, Chen H, Glesby MJ, Busti A, Souza S, Andersen J, et al. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS. 2009;23(16):2133–41. Scholar
  56. 56.
    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. Scholar
  57. 57.
    Kohli M, Patel K, MacMahon, Z, Ramachandran R, Crook MA, Reynolds TM, et al. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017.Google Scholar
  58. 58.
    Dubé MP, Komarow L, Fichtenbaum CJ, Cadden JJ, Overton ET, Hodis HN, et al. Extended-release niacin versus Fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: effects on endothelial function, lipoproteins, and inflammation. Clin Infect Dis. 2015;61(5):840–9. Scholar
  59. 59.
    Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, Iyer D, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metab. 2011;96(7):2236–47. Scholar
  60. 60.
    Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol. 2010;4(4):279–87. Scholar
  61. 61.
    Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis. 2004;172(2):273–9. Scholar
  62. 62.
    Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retrovir. 2005;21(9):757–67. Scholar
  63. 63.
    Muñoz MA, Liu W, Delaney JA, Brown E, Mugavero MJ, Mathews WC, et al. Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. J Acquir Immune Defic Syndr. 2013;64(3):254–60. Scholar
  64. 64.
    Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008;47(4):459–66. Scholar
  65. 65.
    Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179–93. Scholar
  66. 66.
    Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25(2):185–95. Scholar
  67. 67.
    Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204(8):1191–201. Scholar
  68. 68.
    Saumoy M, Ordoñez-Llanos J, Martínez E, Barragán P, Ribera E, Bonet R, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther. 2011;16(4):459–68. Scholar
  69. 69.
    Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–46. Scholar
  70. 70.
    Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229–37. Scholar
  71. 71.
    Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679–88. Scholar
  72. 72.
    Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retrovir. 2012;28(10):1184–95. Scholar
  73. 73.
    Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77–85. Scholar
  74. 74.
    Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–43. Scholar
  75. 75.
    DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Ad M, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35.CrossRefGoogle Scholar
  76. 76.
    Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17(6):1011–20. Scholar
  77. 77.
    Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56(11):1637–45. Scholar
  78. 78.
    Ucciferri C, Falasca K, Vignale F, Di Nicola M, Pizzigallo E, Vecchiet J. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol. 2013;85(5):755–9. Scholar
  79. 79.
    Calza L, Magistrelli E, Colangeli V, Borderi M, Bussini L, Bon I, et al. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infect Dis (Lond). 2017;49(10):737–47. Scholar
  80. 80.
    Lee FJ, Monteiro P, Baker D, Bloch M, Roth N, Finlayson R, et al. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial. HIV Med. 2016;17(8):605–14. Scholar
  81. 81.
    Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396–407. Scholar
  82. 82.
    Martínez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26(18):2315–26. Scholar
  83. 83.
    Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, et al. A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDs. 2012;26(9):532–40. Scholar
  84. 84.
    European AIDS Clinical Society Guidelines for the treatment of HIV-positive adults. Version 9.0 - October 2017. Accessed 15/11/2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.First Department of Internal Medicine, Medical SchoolAristotle University of Thessaloniki, AHEPA HospitalThessalonikiGreece
  2. 2.First Propedeutic Department of Internal Medicine, Medical SchoolAristotle University of Thessaloniki, AHEPA HospitalThessalonikiGreece

Personalised recommendations